Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases

Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic ThERapy (SABER) Study

(2012) Kevin L. Winthrop et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis

(2012) Adam P. Gregory et al.   NATURE

Neurological adverse events associated with anti-tumor necrosis factor alpha treatment

(2010) Antonio G. Tristano   JOURNAL OF NEUROLOGY

Optic Neuritis Associated with Adalimumab in the Treatment of Uveitis

(2010) Sing Your Li et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

(2010) María Cruz Fernández-Espartero et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Long-term Course of Demyelinating Neuropathies Occurring During Tumor Necrosis Factor-α–Blocker Therapy

(2009) Pierre Lozeron et al.   ARCHIVES OF NEUROLOGY

Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention

(2008) Alberto Ascherio et al.   SEMINARS IN NEUROLOGY